Jon Lippiat

Identification of new KCNT1-epilepsy drugs by in silico, cell and Drosophila modelling. https://www.biorxiv.org/content/10.1101/2025.05.22.655336v1

KCNT1 gain-of-function variants cause severe, drug-resistant epilepsies, often with early onset and developmental regression. He we used a multi-model approach, combining computational screening, electrophysiology, and humanized KCNT1 Drosophila to identify existing drugs that inhibit KCNT1.

Identification of New KCNT1‐Epilepsy Drugs by In Silico, Cell, and Drosophila Modeling Objective Hyperactive KCNT1 potassium channels, caused by gain-of-function mutations, are associated with a range of epilepsy disorders. Patients typically experience drug-resistant seizures and, in...

Our newly-published paper: Identification of New KCNT1‐Epilepsy Drugs by In Silico, Cell, and Drosophila Modeling onlinelibrary.wiley.com/doi/10.1002/...

#IonChannels #KCNT1 #RareDisease #DrugDiscovery